Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $9 | $25 | $61 |
| G&A Expenses | $18 | $18 | $26 | $30 |
| SG&A Expenses | $18 | $18 | $26 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $21 | $7 | $1 | $0 |
| Operating Expenses | $57 | $35 | $52 | $90 |
| Operating Income | -$57 | -$35 | -$52 | -$90 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $3 | $0 | $0 |
| Pre-Tax Income | -$57 | -$32 | -$52 | -$90 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$57 | -$31 | -$52 | -$90 |
| % Margin | – | – | – | – |
| EPS | -1.31 | -0.84 | -1.54 | -3.03 |
| % Growth | -56% | 45.5% | 49.2% | – |
| EPS Diluted | -1.31 | -0.84 | -1.54 | -3.03 |
| Weighted Avg Shares Out | 43 | 37 | 33 | 30 |
| Weighted Avg Shares Out Dil | 43 | 37 | 33 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $1 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$36 | -$27 | -$51 | -$90 |
| % Margin | – | – | – | – |